Deutsch  |  English   

Milestones:

2010:
  • GenoType LepraeDR: Identification of Mycobacterium leprae and its resistance to rifampicin, ofloxacin and dapsone
  • GenoType CDiff: molecular genetic assay for detection of Clostridium difficile and ribotype 027. Differentiation of non-pathogenic, virulent and hypervirulent strains
  • GenoXtract: fully automated instrument for the isolation of nucleic acids from various sample
  • GXT Extraction Kits: Extraction Kits for fully automated isolation of nucleic acids from various sample materials with GenoXtract
  • GTQ-Cycler 96: 96-well thermal cycler for nucleic acid amplification
  • GenoScan®: automated evaluation and result interpretation of GenoType- and GenoQuick® assays 
  • SeroCT™ RT IgG und IgA: a new generatrion of ELISAs for the detection of antibodies against Chlamydia trachomatis in human serum at room temperature from Savyon Diagnostics, Israel
  • GenoQuick® MTB: rapid molecular genetic test system for the detection of M. tuberculosis complex
2009:
  • GenoQuick® Bordetella: rapid assay for direct detection of Bordetella pertussis und B. parapertussis from patient specimens
  • GenoType® MTBDRsl: identification of the M. tuberculosis complexes and its resistance to fluoroquinolones and/or aminoglycosides/cyclic peptides and ethambutol from cultivated samples or pulmonary smear-positive clinical specimens
  • Lauch of SepsiTestTM from Molzym, Germany; molecular genetic assay for the detection of more than 345 species (bacteria and yeast) from whole blood
  • Launch of Check-ESBL and Check-KPC ESBL from Check-Points, Netherlands; rapid molecular detection of ESBL and KPC - ESBL
  • Foundation of the subsidiary Hain Lifescience SA (Pty) Ltd with a branch in Midrand, South Africa
  • Expansion of the international distribution network with distributors in China, Hong Kong, Taiwan, India, Latin America, Kazakhstan and Belarus
2008:
  • GenoType® HelicoDR for molecular genetic identification of Helicobacter pylori and its resistance to fluoroquinolones and/or clarithromycin from cultivated samples or biopsy material
  • GenoQuick® CT: Rapid assay for direct detection of Chlamydia trachomatis from patient specimens
  • GenoQuick® HLA-B27: For detection of the HLA-B27 gene
  • Foundation of the subsidiary Hain Lifescience S.L. in Spain with a branch in Vigo, Galicia
  • Foundation of the subsidiary Hain Lifescience East and Central Africa Ltd. with a branch in Nairobi, Kenya 
  • Expansion of the international distribution network with distributors in  Japan, Bosnia and Herzegovina, Romania, Korea, Turkey and Serbia
2007:
  • GenoType® MTBDRplus: identification of the M. tuberculosis complex and its resistance to rifampicin and/or isoniazid from culivated samples or pulmonary smear-positive clinical specimens
  • GenoLyse®: Easy and fast manual extraction of genomic bacterial DNA from patient specimens
  • Induction of a new 1.300 qm company building in Nehren with a lab for trainings, production facility and offices
  • Expansion of the international distribution network with distributors in Canada and Hungary
2006:
  • Implementation of the GenoQuick® technology which provides a new generation of direct tests. The technolgy combines high specificity with maximum sensitivity and rapid results. Minimum technical requirements allow even small laboratories an access to molecular diagnostic.
  • GenoQuick® MRSA: First test system based on the GenoQuick® technology. The GenoQuick® MRSA allows a rapid and specific MRSA detection from patient specimens
  • GenoType® BC grampositive/gramnegative: Identification of gram-positive and gram-negative bacteria from blood culture
  • GENO•CARD®:  Collection of DNA for use in human genetic test systems of the GenoType® product series and GenoType® BC grampositive/gramnegative
  • Expansion of the international distribution network with distributors in Singapore, Malaysia , Thailand, Pakistan, Lithuania and Latvia
2005:
  • GenoType® LCT: Detection of primary lactose intolerance
  • GenoType® MRSA Direct: Detection of MRSA direct from patient specimens without the need to grow cultures
  • GenoType® Staphylococcus: Identification of Staphylococci from cultured material
  • Expansion of the international distribution network with distributors in Poland, Bulgaria, USA and Taiwan
2004:
  • micro-IDent®plus for extended periodontitis diagnostics
  • GenoType® MTBDR: Detection of the M. tuberculosis complex and its most relevant resistance to rifampicin and/or isoniazid
  • GenoType® Mycobacteria Direct: direct detection of the M. tuberculosis complex and four common mycobacteria other than tuberculosis (MOTT)
  • Extension of the GenoType® Mycobacterium by introduction of GenoType® Mycobacterium CM and GenoType® Mycobacterium AS
  • Expansion of the international distribution network with distributors in  Australia, New Zealand, South Africa, Cyprus, Israel, Middle East and Turkey
2002-2003:
  • GenoType® MTBC: Differentiation of the M. tuberculosis complex from cultured material
  • GenoType® EHEC: Detection of shigatoxins and virulence factors
  • GenoType® Enterococcus: Identification of enterococcal species as well as the vancomycin resistance
  • ThromboType®plus for efficient diagnosis of thrombophilia
  • GenoType® PAI-1: Detection of the most relavant PAI-1 polymorphisms
  • GenoType® ApoE: ifferentiation of the most prevalent allels of the ApoE gene
  • Expansion of the international distribution network with distributors in Greece, Croatia,  Finland, Italy, Great Britain, Ireland, Spain, Slovenia and the Czech Republic
2001:
  • Launch of the mycobacterial product series featuring GenoType® Mycobacterium for the culture differentiation of the M. tuberculosis complex and common MOTT
  • GenoType® MRSA: Detection of Staphylococcus aureus und S. epidermidis and the mecA gene from cultured material
  • Launch of SeroCP™ Quant for the semiquantitative detection of antibodies against Chlamydia pneumoniae from Savyon Diagnostics, Israel
  • renaming to Hain Lifescience GmbH
  • Development of an international distribution network in Portugal, BeNeLux, France, Austria  and Switzerland
2000:
  • GenoType® HH: Detection of Hereditary Hemochromatosis and GenoType® AAT for the detection of alpha-1-antitrypsin deficiency
  • Completion of a second office and manufacturing building in Nehren
1999:
  • Start of distribution of Pankreas-Elastase-ELISA from Bioserv Diagnostics in Germany
  • Extension of the thrombophilia series by GenoType® MTHFR
1998:
  • Launch of ThromboType® for the detection of the Factor V Leiden and prothrombin G20210A mutations
1997:
  • Distribution of SeroCT™ und SeroCP™ for the detection of antibodies against Chlamydia trachomatis and Chlamydia pneumoniae from Savyon Diagnostics, Israel
     
1996:
  • Launch of the first test system based on the DNA•STRIP® technology: micro-IDent® or detection of periodonto-pathogenic marker bacteria in tooth pockets
  • Development of the DNA•STRIP® technology which is the basis of the GenoType® product series
1995:
  • Establishment of a nationwide sales force
1992:
  • First own company building in Nehren
1989:
  • Formation of Hain Diagnostika GmbH
1986:
  • Formation of a private company in Reutlingen by David and Tobias Hain: distribution of lab ware in Germany